IntAct European Bioinformatics Institute IntAct intact http://www.ebi.ac.uk/ http://www.ebi.ac.uk/intact/query/${ac} EBI-[0-9]+|IA:[0-9]+ INTerAction database (IntAct) provides an open source database and toolkit for the storage, presentation and analysis of molecular interactions. http://www.ebi.ac.uk/intact European Bioinformatics Institute; Wellcome Trust Genome Campus; Hinxton, Cambridge; CB10 1SD; United Kingdom http://www.ebi.ac.uk/intact/ http://www.ebi.ac.uk/ packer-2011-5 Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. human-d04 Human D04 cells d04 D04 melanoma cells anti tag coip anti tag coimmunoprecipitation anti tag coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Richard.Marais@icr.ac.uk Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation packer-2011-6 Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. human-d04 Human D04 cells d04 D04 melanoma cells anti tag coip anti tag coimmunoprecipitation anti tag coip anti tag western anti tag western blot anti tag western Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Richard.Marais@icr.ac.uk Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation packer-2011-10 Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. human-k_562 Homo sapiens myeloid leukemia cells. k562 Myelogenous leukemia K562 cells anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Richard.Marais@icr.ac.uk Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation packer-2011-1 Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. human-d04 Human D04 cells d04 D04 melanoma cells anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Richard.Marais@icr.ac.uk Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation packer-2011-2 Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. human-sw620 Human caucasian colon adenocarcinoma SW620 cells sw620 Human caucasian colon adenocarcinoma SW620 cells anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Richard.Marais@icr.ac.uk Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation packer-2011-3 Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. human-h460 Homo sapiens non-small-cell lung cancer cell line H460 h460 human non-small-cell lung cancer cell line H460 anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Richard.Marais@icr.ac.uk Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation packer-2011-4 Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. human-panc1 Homo sapiens pancreatic carcinoma cell line PANC-1 panc1 Human pancreatic carcinoma cell line PANC-1 Established from a pancreatic carcinoma of ductal origin from a 56-year-old Caucasian male. Cells possess the type B phenotype for G6PD. anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Richard.Marais@icr.ac.uk Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation packer-2011-7 Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. human-d04 Human D04 cells d04 D04 melanoma cells anti bait coip anti bait coimmunoprecipitation anti bait coip anti tag western anti tag western blot anti tag western Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Richard.Marais@icr.ac.uk Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation packer-2011-8 Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. mouse-ba_f3 Mouse pro B cells IL-3 dependent mouse-baf3 EBI-6922762 ba_f3 Mouse pro B cells IL-3 dependent BA/F3 baf3 Mouse pro B cell line. IL-3 dependent murine pro B cell line established from peripheral blood; apparently derived from BALB/c mouse. anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Cells were transfected with Human BCR-ABL fusion protein (p185), with or without the T315I mutation, and with or without several other mutations. Richard.Marais@icr.ac.uk Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation packer-2011-9 Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. human-bv173r BV173R- Human imatinib –resistant variant of BV173 expressing T315I mutation Bcr/Abl bv173r BV173R- Human, imatinib –resistant variant of BV173 expressing T315I mutation Bcr/Abl derived from a patient with CML in lymphoblastic crisis anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Packer L.M., Rana S., Hayward R., O'Hare T., Eide C.A., Rebocho A., Heidorn S., Zabriskie M.S., Niculescu-Duvaz I., Druker B.J., Springer C., Marais R. Cancer - Interactions investigated in the context of cancer Richard.Marais@icr.ac.uk Cancer Cell (1535-6108) 2011 Only protein-protein interactions imex curation braf_human Serine/threonine-protein kinase B-raf BRAF BRAF1 RAFB1 v-Raf murine sarcoma viral oncogene homolog B1 p94 Proto-oncogene B-Raf protein protein human Homo sapiens Human MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH raf1_human RAF proto-oncogene serine/threonine-protein kinase RAF1 RAF Proto-oncogene c-RAF Raf-1 protein protein human Homo sapiens Human MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF rash_human GTPase HRas HRAS HRAS1 Transforming protein p21 p21ras H-Ras-1 c-H-ras Ha-Ras protein protein human Homo sapiens Human MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQHKLRKLNPPDESGPGCMSCKCVLS raf1_mouse RAF proto-oncogene serine/threonine-protein kinase Raf1 Craf Proto-oncogene c-RAF Raf-1 protein protein mouse Mus musculus Mouse MEHIQGAWKTISNGFGLKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDSSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLQEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTVGDSGVPAPPSFPMRRMRESVSRMPASSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLHVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPGSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQLQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDDNPFSFQSDVYSYGIVLYELMAGELPYAHINNRDQIIFMVGRGYASPDLSRLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF braf_mouse Serine/threonine-protein kinase B-raf Braf B-raf Proto-oncogene B-Raf protein protein mouse Mus musculus Mouse MAALSGGGGSSSGGGGGGGGGGGGGDGGGGAEQGQALFNGDMEPEAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLVFQTPTDASRNNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPVPQEEASFPETALPSGSSSAPPSDSTGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSSSEDRSRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGGFPVH braf-raf1-21 1253890 n/a 1253900 unspecified role unspecified role bait bait P15056:p.Arg188Leu mutation disrupting mutation disrupting interaction mutation disrupting certain certain sequence position certain certain certain sequence position certain false n_terminus myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range false n/a 1253901 unspecified role unspecified role prey prey physical association physical association false false false 2D Nilotinib Mutations that prevented BRAF (BRAFR188L) or CRAF (CRAFR89L) binding to RAS blocked BRAF binding to CRAF. raf1-braf-4 1253890 n/a 1253900 unspecified role unspecified role prey prey n/a 1253901 unspecified role unspecified role bait bait P04049:p.Arg89Leu mutation disrupting mutation disrupting interaction mutation disrupting certain certain sequence position certain certain certain sequence position certain false n_terminus myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range false physical association physical association false false false 2E Nilotinib Mutations that prevented BRAF (BRAFR188L) or CRAF (CRAFR89L) binding to RAS blocked BRAF binding to CRAF. braf-raf1-22 1253890 n/a 1253901 unspecified role unspecified role prey prey n/a 1253900 unspecified role unspecified role bait bait P15056:p.Arg188Asn mutation disrupting mutation disrupting interaction mutation disrupting certain certain sequence position certain certain certain sequence position certain false n_terminus flag tag flag tag FLAG-tagged FLAG DYKDDDDKV epitope tag DYKDDDDKV epitope tag FLAG FLAG-tagged n-term range n-terminal range n-term range n-term range n-terminal range n-term range false physical association physical association false false false S2B Dastinib Mutations BRAF - T529N and CRAF - T421N severely impaired the ability to form BRAF:CRAF heterodimers and BRAF:BRAF or CRAF:CRAF homodimers. braf-braf1-22 1253891 n/a 1253900 unspecified role unspecified role bait bait n_terminus myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range false P15056:p.Thr529Asn mutation disrupting mutation disrupting interaction mutation disrupting certain certain sequence position certain certain certain sequence position certain false n/a 1253900 unspecified role unspecified role prey prey n_terminus ha tag ha tag YPYDVPDYA epitope tag YPYDVPDYA epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range false physical association physical association false false false 2G, 2I. Nilotinib BRAF and CRAF homodimers were formed in D04 cells (Figures 2F and 2G). Mutations BRAF - T529N and CRAF - T421N severely impaired the ability to form BRAF:CRAF heterodimers and BRAF:BRAF or CRAF:CRAF homodimers. raf1-raf-5 1253891 n/a 1253901 unspecified role unspecified role prey prey n_terminus ha tag ha tag YPYDVPDYA epitope tag YPYDVPDYA epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range false n/a 1253901 unspecified role unspecified role bait bait n_terminus myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range false physical association physical association false false false 2F Nilotinib BRAF and CRAF homodimers were formed in D04 cells (Figures 2F and 2G). raf1-raf1-1 1253891 n/a 1253901 unspecified role unspecified role bait bait n_terminus flag tag flag tag FLAG-tagged FLAG DYKDDDDKV epitope tag DYKDDDDKV epitope tag FLAG FLAG-tagged n-term range n-terminal range n-term range n-term range n-terminal range n-term range false P04049:p.Thr421Asn mutation disrupting mutation disrupting interaction mutation disrupting certain certain sequence position certain certain certain sequence position certain false n/a 1253901 unspecified role unspecified role prey prey n_terminus myc tag myc tag EUKLISEED epitope tag EUKLISEED epitope tag n-term range n-terminal range n-term range n-term range n-terminal range n-term range false physical association physical association false false false 2J Nilotinib Mutations BRAF - T529N and CRAF - T421N severely impaired the ability to form BRAF:CRAF heterodimers and BRAF:BRAF or CRAF:CRAF homodimers. raf1-braf-9 1253892 n/a 1253902 unspecified role unspecified role ancillary ancillary P01112:p.Gly12Val mutation mutation certain certain sequence position certain certain certain sequence position certain false n/a 1253901 unspecified role unspecified role bait bait n/a 1253900 unspecified role unspecified role prey prey physical association physical association false false false 4C Imatinib, nilotinib, and dasatinib imatinib, nilotinib, and dasatinib did not induce BRAF binding to CRAF in K562 cells (which express BCR-ABL), but when these cells expressed HRAS - G12V, all three drugs induced BRAF binding to CRAF. raf1-braf-10 1253892 n/a 1253901 unspecified role unspecified role bait bait n/a 1253900 unspecified role unspecified role prey prey physical association physical association false false false S3E nilotinib BRAF binding to CRAF was observed in K562R cells (a clone of K562 cells that is resistant to Imatinib due to overexpression of the SRC family kinase LYN). raf1-braf 1253893 n/a 1253900 unspecified role unspecified role prey prey n/a 1253901 unspecified role unspecified role bait bait physical association physical association false false false 2B Imatinib, nilotinib, and dasatinib all induced robust BRAF binding to CRAF in cells expressing oncogenic RAS (D04, SW620, H460, and Panc1 cells). raf1-braf-1 1253894 n/a 1253901 unspecified role unspecified role bait bait n/a 1253900 unspecified role unspecified role prey prey physical association physical association false false false 2C Imatinib, nilotinib, and dasatinib all induced robust BRAF binding to CRAF in cells expressing oncogenic RAS (D04, SW620, H460, and Panc1 cells). raf1-braf-2 1253895 n/a 1253901 unspecified role unspecified role bait bait n/a 1253900 unspecified role unspecified role prey prey physical association physical association false false false 2C Imatinib, nilotinib, and dasatinib all induced robust BRAF binding to CRAF in cells expressing oncogenic RAS (D04, SW620, H460, and Panc1 cells). raf1-braf-3 1253896 n/a 1253900 unspecified role unspecified role prey prey n/a 1253901 unspecified role unspecified role bait bait physical association physical association false false false 2C Imatinib, nilotinib, and dasatinib all induced robust BRAF binding to CRAF in cells expressing oncogenic RAS (D04, SW620, H460, and Panc1 cells). raf1-braf-6 1253897 n/a 1253901 unspecified role unspecified role bait bait n/a 1253900 unspecified role unspecified role prey prey P15056:p.Thr529Asn mutation disrupting mutation disrupting interaction mutation disrupting certain certain sequence position certain certain certain sequence position certain false n_terminus flag tag flag tag FLAG-tagged FLAG DYKDDDDKV epitope tag DYKDDDDKV epitope tag FLAG FLAG-tagged n-term range n-terminal range n-term range n-term range n-terminal range n-term range false physical association physical association false false false 2H Nilotinib and Imatinab. Mutations BRAF T529N and CRAF T421N were severely impaired in their ability to form BRAF:CRAF heterodimers and BRAF:BRAF or CRAF:CRAF homodimers. braf-raf1-24 1253898 n/a 1253903 unspecified role unspecified role prey prey n/a 1253904 unspecified role unspecified role bait bait physical association physical association false false false 3C, 4G, 5F, S3C, S3D. Imatinib, nilotinib, and dasatinib did not affect BRAF binding to CRAF in BCR-ABL cells, but they enhanced BRAF binding to CRAF in BCR-ABL T315I Ba/F3 cells. Imatinib, nilotinib, and dasatinib, in BCR-ABL T315I Ba/F3 cells. BRAF selective inhibitors SB590885 and L779450, enhanced BRAF binding to CRAF in BCR-ABL Ba/F3 cells. pan-RAF inhibitors sorafenib and RAF265 induced BRAF binding to CRAF in BCR-ABL T315I Ba/F3 cells. BRAF inhibitor PLX4720 and the MEK inhibitor PD184352 , induced only weak BRAF binding to CRAF, in BCR-ABL T315I Ba/F3 cells. Cells expressing BCR-ABL G250E/T315I, BCR-ABL E255K/T315I, or BCR-ABL E255V/T315 induced BRAF binding to CRAF. raf1-braf-7 1253899 n/a 1253900 unspecified role unspecified role prey prey n/a 1253901 unspecified role unspecified role bait bait physical association physical association false false false 3E Imatinib, nilotinib, and dasatinib imatinib, nilotinib, and dasatinib did not induce BRAF binding to CRAF in BV173 cells, but they did induce BRAF binding to CRAF in BV173R cells, which express BCR-ABL T315I.